Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1974 1
1979 2
1980 1
1982 2
1983 6
1984 2
1985 3
1986 3
1988 3
1989 2
1990 12
1991 8
1992 11
1993 4
1994 2
1995 10
1996 7
1997 5
1998 5
1999 4
2000 3
2001 3
2002 9
2003 6
2004 3
2005 4
2006 3
2007 3
2008 9
2009 6
2010 5
2011 9
2012 5
2013 5
2014 4
2015 10
2016 13
2017 7
2018 10
2019 4
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

200 results
Results by year
Filters applied: . Clear all
Page 1
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M. Yuki S, et al. Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25. Cancer Chemother Pharmacol. 2020. PMID: 31768696 Clinical Trial.
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y. Oki E, et al. Br J Cancer. 2019 Jul;121(3):222-229. doi: 10.1038/s41416-019-0518-2. Epub 2019 Jul 9. Br J Cancer. 2019. PMID: 31285591 Free PMC article. Clinical Trial.
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A. Oki E, et al. Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9. Clin Colorectal Cancer. 2018. PMID: 29530335 Free article. Clinical Trial.
Recent advances in treatment for colorectal liver metastasis.
Oki E, Ando K, Nakanishi R, Sugiyama M, Nakashima Y, Kubo N, Kudou K, Saeki H, Nozoe T, Emi Y, Maehara Y. Oki E, et al. Ann Gastroenterol Surg. 2018 Apr 17;2(3):167-175. doi: 10.1002/ags3.12071. eCollection 2018 May. Ann Gastroenterol Surg. 2018. PMID: 29863162 Free PMC article. Review.
Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial.
Maehara Y, Shirabe K, Kohnoe S, Emi Y, Oki E, Kakeji Y, Baba H, Ikeda M, Kobayashi M, Takayama T, Natsugoe S, Haraguchi M, Yoshida K, Terashima M, Sasako M, Yamaue H, Kokudo N, Uesaka K, Uemoto S, Kosuge T, Sawa Y, Shimada M, Doki Y, Yamamoto M, Taketomi A, Takeuchi M, Akazawa K, Yamanaka T, Shimokawa M. Maehara Y, et al. Surg Today. 2017 Sep;47(9):1060-1071. doi: 10.1007/s00595-017-1480-3. Epub 2017 Feb 23. Surg Today. 2017. PMID: 28233105 Review.
Angiogenesis as a target for gastric cancer.
Kakeji Y, Maehara Y, Sumiyoshi Y, Oda S, Emi Y. Kakeji Y, et al. Surgery. 2002 Jan;131(1 Suppl):S48-54. doi: 10.1067/msy.2002.119304. Surgery. 2002. PMID: 11821787 Review.
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307).
Saeki H, Jogo T, Kawazoe T, Kamori T, Nakaji Y, Zaitsu Y, Fujiwara M, Baba Y, Nakamura T, Iwata N, Egashira A, Nakanoko T, Morita M, Tanaka Y, Kimura Y, Shibata T, Nakashima Y, Emi Y, Makiyama A, Oki E, Tokunaga S, Shimokawa M, Mori M; Kyushu Study Group of Clinical Cancer (KSCC). Saeki H, et al. Ann Surg. 2020 May 29. doi: 10.1097/SLA.0000000000003975. Online ahead of print. Ann Surg. 2020. PMID: 32482981
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
Ando K, Emi Y, Miyanari N, Tsuji A, Sakai K, Sawai T, Imamura H, Mori S, Tokunaga S, Oki E, Saeki H, Kakeji Y, Akagi Y, Baba H, Maehara Y, Mori M; Kyushu Study Group of Clinical Cancer (KSCC). Ando K, et al. Int J Clin Oncol. 2020 Jun;25(6):1115-1122. doi: 10.1007/s10147-020-01646-5. Epub 2020 Mar 18. Int J Clin Oncol. 2020. PMID: 32189156 Clinical Trial.
200 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page